vildagliptin

Drug #2231

vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the amount of two incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are normally produced naturally by the body in response to food intake. Their function is to help control blood sugar (glucose) levels. It is used to treat type 2 or non-insulin dependent diabetes (NIDDM) in combination with a sulphonylurea (50 mg once daily), metformin or a glitazone (50 mg twice daily).

← Previous drug Next drug →

Primary Characteristics

It belongs to DPP-4 inhibitor pharmacological group on the basis of mechanism of action.

Molecular Weight: 303.4 · Solubility in Water: 1.75e+00 g/l · Non-proprietary name: vildagliptin.

Pharmacokinetics

Absorption: vildagliptin has an oral bioavailability is 85%.

Distribution: vildagliptin has a volume of distribution is Vss 71 liters after IV administration. plasma protein binding is 9.3%.

Elimination: it is metabolised via mainly by hydrolysis in Kidney, plasma half-life is 90 minutes, renal excretion is 85% in urine and 15% in faeces..

Indications

vildagliptin is primarily indicated in conditions like Type II diabetes mellitus.

Contraindications

vildagliptin is contraindicated in conditions like Hypersensitivity to the drug.

Dosage

vildagliptin's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
50 mg	50 mg	Every 12h	oral	When used in dual combination with metformin or a thiazolidinedione. It can be taken with or without food. No dose adjustment is required in patients with mild renal impairment (creatinine clearance GREATER-THAN OR EQUAL TO 50ml/min). The use of vildagliptin is not recommended in patients with moderate or severe renal impairment or in haemodialysis patients with end-stage renal disease (ESRD).
75 mg	75 mg	Every 24h	oral	When used in dual combination with a sulphonylurea it is recommended once daily. Doses higher than 100mg are not recommended. It can be taken with or without food. It is not recommended for use in children (less then 18 years) and adolescents due to a lack of data on safety and efficacy.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

vildagliptin produces potentially life-threatening effects which include Angioedema . Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of vildagliptin are Muscle aches, Swelling of feet and lower legs, Fever, Mild paresthesia.

vildagliptin is known to cause more or less tolerable side effects which are usually transient. These include Asthenia , Dizziness, Fatigue, Headache, Hypoglycemia, Nausea.

Warnings / Precautions

Do not use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. not recommended in ESRD on haemodialysis patients. Do not use in patients with hepatic impairment, including patients with pre-treatment ALT or AST > 3x ULN. Liver function should be monitored during treatment with vildagliptin at three-month intervals during the first year and periodically thereafter. Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue it. Following withdrawal of treatment with vildagliptin and LFT normalisation, treatment with vildagliptin should not be reinitiated. Monitoring for skin disorders, such as blistering or ulceration, is recommended while keeping with routine care of the diabetic patient.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

50 mg

Multi-Ingredient Combinations

Tabs

50 mg

Storage Conditions

vildagliptin should be stored tablet.

Drug Classification

1.18.7.2 — Oral hypoglycemics

Manufacturers

Manufacturers of vildagliptin in Pakistan:

Atco High-Q Novartis Tabros